Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT2 | P34897 | 3/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466408 | 0.80 | CTSK (0.43) | SHMT2CTSK | |
| SCHEMBL5105668 | 0.77 | PDE4B (0.39) | ALDH1A1LMNA | |
| SCHEMBL4689693 | 0.77 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL5098778 | 0.75 | CYP2C19 (0.44) | ALDH1A1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL6355386 | 0.74 | PDE5A (0.37) | SMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL5092936 | 0.73 | RAB9A (0.45) | LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL6203392 | 0.72 | BTK (0.32) | KMT2A | |
| SCHEMBL5096673 | 0.72 | CCR8 (0.35) | CTSKKMT2A | |
| SCHEMBL4693518 | 0.72 | CTSK (0.41) | CTSKALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL5099322 | 0.71 | AKR1C3 (0.35) | ALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203084-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203084-A1 | Protease inhibitors | SERPINB1, SPINT2, PRSS1 | SHMT2 4852/4885CTSK 72/4885ALDH1A1 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.